Trial | NCT00960245  Report issue

Title

Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    nadolol ...

  • Study Participants

    34
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
Study Started
Jul 31
1994
Primary Completion
Jul 31
1994
Study Completion
Jul 31
1994
Last Update
Mar 28
2017

Drug Nadolol (1 x 80 mg) Tablets (Invamed, Inc)

Drug Corgard (1 x 80 mg) Tablets (Bristol Laboratories)

1 Experimental

Nadolol (1 x 80 mg) Tablets (Invamed, Inc)

2 Active Comparator

Corgard (1 x 80 mg) Tablets (Bristol Laboratories)

Criteria 

Inclusion Criteria:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.
No Results Posted